(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst - 2SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- 3Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- 4Rescuers again fail to free whale stranded on Germany's Baltic coast
- 5The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- How will the universe end?
- The Best Games Crossroads in History
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- Vote in favor of Your Number one Cake Type
- Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- Exemplary Fragrances: A Manual for Notorious Scents
- Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
